Issue Date: June 6, 2016
Iceni to repurpose Merck’s cilengitide
Scottish DNA vaccines developer BigDNA has renamed itself Iceni Pharmaceuticals and relaunched to focus on repurposed cancer therapies. The firm’s lead candidate is cilengitide, a cyclic peptide. Cilengitide was initially developed by the Technical University of Munich and Merck KGaA, but it failed late-stage clinical trials for treating glioblastoma, an aggressive brain cancer. Iceni has demonstrated in preclinical trials that cilengitide is effective in a combination therapy for treating myeloma, a bone cancer. Iceni plans to begin Phase II trials in 2017.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society